Search | Clinical Trials Finder

Conditions: Type 2 Diabetes Mellitus
Interventions: Bexagliflozin; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Lakewood, Colorado

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo identical to BI 1356 5mg, Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg, BI 1356, Glimepiride; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 23
States / cities: Tempe, Arizona • Chula Vista, California • Los Angeles, California + 19 more

Conditions: Diabetic Kidney Disease
Interventions: BMS-813160, Placebo matching with BMS-813160; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more

Conditions: Diabetes (DM)
Interventions: Food is medicine; Dietary Supplement
Lead sponsor: Public Health Institute Center for Wellness and Nutrition; Other
Eligibility: 18 Years and older
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Stockton, California

Conditions: Diabetes Mellitus, Type 1
Interventions: Insulin Lispro Protamine Suspension, Insulin Levemir; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Idaho Falls, Idaho • Springfield, Illinois • Topeka, Kansas + 1 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 45
States / cities: Huntsville, Alabama • Goodyear, Arizona • Mesa, Arizona + 40 more

Conditions: Diabetes Mellitus Type 2
Interventions: Placebo, RO5027838, RO5093151; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 2
States / cities: Chula Vista, California • Miami, Florida

Conditions: Diabetes Mellitus, Type 2
Interventions: Exubera (inhaled insulin), 8-point glucose diary (to assess pre- and post prandial glucoses), Meal Tolerance Test, 24-hour continuous glucose monitoring (at select sites), Pulmonary Function Testing, Hypoglycemic Event Monitoring, Laboratory Assessments, Nutritional Counseling and Diabetes Education; Drug · Procedure · Behavioral
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • New Britain, Connecticut + 13 more

Conditions: Healthy Volunteers, Type 2 Diabetes
Interventions: Semaglutide D Dose 1, Semaglutide D Dose 2, Semaglutide D Dose 3, Semaglutide Dose 4, Semaglutide Dose 5, Semaglutide Dose 6; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 546 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Cypress, California • Overland Park, Kansas

Conditions: Type 2 Diabetes Mellitus
Interventions: 300 mg LX4211 (150 mg tablets), 300 mg LX4211 (50 mg tablets), 300 mg LX4211 (liquid); Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetic Kidney Disease
Interventions: INV-202, Placebo; Drug
Lead sponsor: Inversago Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 23
States / cities: Garden Grove, California • Pomona, California • Salinas, California + 19 more

Conditions: Type II Diabetes
Interventions: AZD1656; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type 2 Diabetes, Vitamin B12 Deficiency, Neuropathy, Anemia
Interventions: Office visit intervention, Electronic Message Intervention; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin icodec, Insulin Glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 12
States / cities: Anaheim, California • Lancaster, California • Roswell, Georgia + 8 more

Conditions: Type 2 Diabetes
Interventions: AZD1656, Glucagon; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Healthy Participants
Interventions: AZD5004, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: Single Dose PB1023; Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Type 1 Diabetes
Interventions: Transition Social Behavioral Intervention, Diabetes Transition Clinic; Behavioral
Lead sponsor: University of Kansas; Other
Eligibility: 16 Years to 29 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec/insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 28
States / cities: Goodyear, Arizona • Anaheim, California • Greenbrae, California + 24 more

Conditions: Type 2 Diabetes Mellitus, Obesity
Interventions: Lifestyle Modification; Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: insulin degludec, insulin glargine, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 9
States / cities: Walnut Creek, California • Honolulu, Hawaii • Idaho Falls, Idaho + 5 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin; Drug · Device
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
Interventions: dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon), dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin detemir; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 66
States / cities: Goodyear, Arizona • Scottsdale, Arizona • Searcy, Arkansas + 55 more

Search by objective public record fields.

Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

Evaluation of the Impact of a Food is Medicine Program on Diabetes-related Health Outcomes for People With Type 2 Diabetes in a Low Income Community-based Setting Compared to Usual Care

Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes

Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus

A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin

US Inhaled Insulin Dose Titration Study

A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People

Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus

Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease

To Evaluate 24-hr Glucose After OD vs BD AZD1656

Comparison of Two Pharmacist-led Population Management Approaches to Increase Monitoring of Vitamin B12 and Serum Creatinine Levels for Patients on Metformin

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

To Evaluate the Response to Glucagon During Hypoglycemia

A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants

Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus

Transition of Adolescents and Young Adults With Diabetes From Pediatric to Adult Care

Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine

A Trial of Two Diets for Weight and Diabetes Management

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily